193 related articles for article (PubMed ID: 30877373)
1. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Diamantopoulos PT; Kontandreopoulou CN; Symeonidis A; Kotsianidis I; Pappa V; Galanopoulos A; Vassilakopoulos T; Dimou M; Solomou E; Kyrtsonis MC; Siakantaris M; Angelopoulou M; Kourakli A; Papageorgiou S; Christopoulou G; Roumelioti M; Panayiotidis P; Viniou NA;
Ann Hematol; 2019 Jun; 98(6):1383-1392. PubMed ID: 30877373
[TBL] [Abstract][Full Text] [Related]
2. Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.
Diamantopoulos P; Zervakis K; Zervakis P; Sofotasiou M; Vassilakopoulos T; Kotsianidis I; Symeonidis A; Pappa V; Galanopoulos A; Solomou E; Kodandreopoulou E; Papadopoulou V; Korkolopoulou P; Mantzourani M; Kyriakakis G; Viniou NA
Blood Cancer J; 2017 Feb; 7(2):e533. PubMed ID: 28212373
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine.
Kontandreopoulou CN; Diamantopoulos PT; Giannopoulos A; Symeonidis A; Kotsianidis I; Pappa V; Galanopoulos A; Panayiotidis P; Dimou M; Solomou E; Loupis T; Zoi K; Giannakopoulou N; Dryllis G; Hatzidavid S; Viniou NA;
Leuk Lymphoma; 2022 Mar; 63(3):729-737. PubMed ID: 34738857
[TBL] [Abstract][Full Text] [Related]
4. PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes.
Gotoh N; Minato Y; Saitoh T; Takahashi N; Kasamatsu T; Souma K; Oda T; Hoshino T; Sakura T; Ishizaki T; Shimizu H; Takizawa M; Yokohama A; Tsukamoto N; Handa H; Murakami H
Eur J Haematol; 2020 Jun; 104(6):526-537. PubMed ID: 32003046
[TBL] [Abstract][Full Text] [Related]
5. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
[TBL] [Abstract][Full Text] [Related]
6. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Mittelman M; Filanovsky K; Ofran Y; Rosenbaum H; Raanani P; Braester A; Goldschmidt N; Kirgner I; Herishanu Y; Perri C; Ellis M; Oster HS;
Ann Hematol; 2016 Oct; 95(11):1811-8. PubMed ID: 27546027
[TBL] [Abstract][Full Text] [Related]
7. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
[TBL] [Abstract][Full Text] [Related]
8. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
Mpakou V; Spathis A; Bouchla A; Tsakiraki Z; Kontsioti F; Papageorgiou S; Bazani E; Gkontopoulos K; Thomopoulos T; Glezou I; Galanopoulos A; Symeonidis A; Diamantopoulos PT; Viniou NA; Kontandreopoulou CN; Zafeiropoulou K; Kotsianidis I; Lamprianidou E; Foukas P; Mpamias A; Pappa V
Hematol Oncol; 2021 Apr; 39(2):231-242. PubMed ID: 33332639
[TBL] [Abstract][Full Text] [Related]
9. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine.
Raj K; John A; Ho A; Chronis C; Khan S; Samuel J; Pomplun S; Thomas NS; Mufti GJ
Leukemia; 2007 Sep; 21(9):1937-44. PubMed ID: 17611569
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Chien KS; Kim K; Nogueras-Gonzalez GM; Borthakur G; Naqvi K; Daver NG; Montalban-Bravo G; Cortes JE; DiNardo CD; Jabbour E; Alvarado Y; Andreeff M; Bose P; Jain N; Kadia TM; Huang X; Sheppard KB; Klingner-Winton C; Pierce SA; Dong XQ; Soltysiak KA; Kantarjian HM; Garcia-Manero G
Br J Haematol; 2021 Nov; 195(3):378-387. PubMed ID: 34340254
[TBL] [Abstract][Full Text] [Related]
11. 5-Azacytidine for the treatment of myelodysplastic syndromes.
Krawczyk J; Keane N; Freeman CL; Swords R; O'Dwyer M; Giles FJ
Expert Opin Pharmacother; 2013 Jun; 14(9):1255-68. PubMed ID: 23621771
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.
Tong H; Hu C; Zhuang Z; Wang L; Jin J
Leuk Lymphoma; 2012 Dec; 53(12):2412-8. PubMed ID: 22632108
[TBL] [Abstract][Full Text] [Related]
13. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidine.
Müller-Thomas C; Heider M; Piontek G; Schlensog M; Bassermann F; Kirchner T; Germing U; Götze KS; Rudelius M
Br J Haematol; 2020 Aug; 190(3):361-370. PubMed ID: 32350858
[TBL] [Abstract][Full Text] [Related]
15. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
[TBL] [Abstract][Full Text] [Related]
16. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
Gawlitza AL; Speith J; Rinke J; Sajzew R; Müller EK; Schäfer V; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2835-2843. PubMed ID: 31506740
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
18. 5-Azacytidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive Patients.
Diamantopoulos P; Zervakis K; Papadopoulou V; Iliakis T; Kalala F; Giannakopoulou N; Rougala N; Galanopoulos A; Bakarakos P; Variami E; Dimitrakopoulou A; Viniou NA
Anticancer Res; 2015 Sep; 35(9):5141-7. PubMed ID: 26254419
[TBL] [Abstract][Full Text] [Related]
19. Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes.
Matsumoto T; Murakami Y; Yoshida-Sakai N; Katsuchi D; Kanazawa K; Okamura T; Imamura Y; Ono M; Kuwano M
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731802
[TBL] [Abstract][Full Text] [Related]
20. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells.
Khan R; Schmidt-Mende J; Karimi M; Gogvadze V; Hassan M; Ekström TJ; Zhivotovsky B; Hellström-Lindberg E
Exp Hematol; 2008 Feb; 36(2):149-57. PubMed ID: 18206726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
